Ranganathan N.,Kibow Biotech Inc. |
Ranganathan P.,Kibow Biotech Inc. |
Friedman E.A.,New York University |
Joseph A.,New York University |
And 6 more authors.
Advances in Therapy | Year: 2010
Introduction: Uremic syndrome consists of nitrogenous waste retention, deficiency in kidney-derived hormones, and reduced acid excretion, and, if untreated, may progress to coma and eventual death. Previous experience suggests that oral administration of a probiotic formulation of selected microbial strains may extend renoprotection via intraintestinal extraction of toxic waste solutes in patients with chronic kidney disease (CKD)stages 3 and 4. This report presents preliminary data from a pilot study. Methods: This was a 6-month prospective, randomized, double-blind, placebo-controlled crossover trial of a probiotic bacterial formulation conducted in four countries, at five institutions, on 46 outpatients with CKD stages 3 an nd 4: USA (n=10), Canada (n=113), Nigeria (n=115), and Argentina (n=8). Outcomes were compared using biochemical parameters:blood urea nitrogen (BUN), serum creatinine, and uric acid. General well-being was assessed as a secondary parameter by a quality of life (QQOL) questionnaire on a subjective scale of 1-10. Results: Oral ingestion of probiotics (90 billion colony forming units [CFUs]/day) was well tolerated and safe during the entire trial period at all sites. BUN levels decreased in 29 patients (63%, P<0.05), creatinine levels decreased in 20 patients (43%, no statistical significance), and uric acid levels decreased in 15 patients (33%, no statistical significance). Almost all subjects expressed a perceived substantial overall improvement in QOL (86%, P<0.05). Conclusion: The main outcomes of this preliminary trial include a significant reduction of BUN, enhanced well-being, and absence of serious adverse effects, thus supporting the use of the chosen probiotic formulation for bowel-based toxic solute extraction. QOL and BUN levels showed statistically significant differences in outcome (P<0.05) between placebo and probiotic treatment periods at all four sites (46 patients). A major limitation of this trial is the small sample size nd elated inconsistencies. © The Author(s) 2010.
Vyas U.,Kibow Biotech Inc. |
Ranganathan N.,Kibow Biotech Inc.
Gastroenterology Research and Practice | Year: 2012
The human intestinal tract has been colonized by thousands of species of bacteria during the coevolution of man and microbes. Gut-borne microbes outnumber the total number of body tissue cells by a factor of ten. Recent metagenomic analysis of the human gut microbiota has revealed the presence of some 3.3 million genes, as compared to the mere 23 thousand genes present in the cells of the tissues in the entire human body. Evidence for various beneficial roles of the intestinal microbiota in human health and disease is expanding rapidly. Perturbation of the intestinal microbiota may lead to chronic diseases such as autoimmune diseases, colon cancers, gastric ulcers, cardiovascular disease, functional bowel diseases, and obesity. Restoration of the gut microbiota may be difficult to accomplish, but the use of probiotics has led to promising results in a large number of well-designed (clinical) studies. Microbiomics has spurred a dramatic increase in scientific, industrial, and public interest in probiotics and prebiotics as possible agents for gut microbiota management and control. Genomics and bioinformatics tools may allow us to establish mechanistic relationships among gut microbiota, health status, and the effects of drugs in the individual. This will hopefully provide perspectives for personalized gut microbiota management. © 2012 Usha Vyas and Natarajan Ranganathan.
Kibow Biotech Inc. | Date: 2013-01-22
This invention is a composition containing prebiotics, Lentinula edodes mycelia extract, and Litchi chinensis fruit polyphenol and use of the same in increasing the effectiveness of radiation or chemotherapy and in the prevention, mitigation and/or treatment of colorectal neoplasia.
Kibow Biotech Inc. | Date: 2012-09-04
The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment.
Kibow Biotech Inc. | Date: 2013-07-09
A composition composed of a Lactobacillus bacterium, Bifidobacterium longum, and xylooligosaccharide is provided for use in reducing uric acid levels in the blood and preventing or treating hyperuricemia or gout.
Kibow Biotech Inc. | Date: 2011-09-12
A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise Lactobacillus, Bacillus, Streptococcus Bifidobacteria, Saccharomyces or Leuconostoc. The isolated protein may comprise whey proteins, whey growth factor extract, glutamine peptide, egg albumen, soy proteins, or caseinates. This nutritional composition can be in the form of a food product, dietary supplement, or medical food which, upon ingestion, will promote a healthy intestinal microenvironment, provide a source of protein, and assist in the elimination of nitrogenous waste products that can build up in concentration in the circulating blood. Increased concentrations of the wastes are known to exert a negative impact on an individuals physiology and contribute to a decreased sense of well-being and general malaise. Methods for removing nitrogenous waste products from the blood and ameliorating renal failure using the nutritional product of the invention are also provided.
Kibow Biotech Inc. | Date: 2010-09-27
The present invention provides a nutritional food product composed of a prebiotic and an isolated protein for use in reducing elevated levels of nitrogenous waste products in the blood and ameliorating renal failure.
Kibow Biotech Inc. | Date: 2014-09-24
Kibow Biotech Inc. | Date: 2011-04-14
Pharmaceutical, nutritional and veterinary preparations for use in treating and helping maintain renal function and kidney health.
Kibow Biotech Inc. | Date: 2014-04-14
prebiotic dietary supplement.